Literature DB >> 20974172

Oxidative stress in schizophrenia: an integrated approach.

Byron K Y Bitanihirwe1, Tsung-Ung W Woo.   

Abstract

Oxidative stress has been suggested to contribute to the pathophysiology of schizophrenia. In particular, oxidative damage to lipids, proteins, and DNA as observed in schizophrenia is known to impair cell viability and function, which may subsequently account for the deteriorating course of the illness. Currently available evidence points towards an alteration in the activities of enzymatic and nonenzymatic antioxidant systems in schizophrenia. In fact, experimental models have demonstrated that oxidative stress induces behavioral and molecular anomalies strikingly similar to those observed in schizophrenia. These findings suggest that oxidative stress is intimately linked to a variety of pathophysiological processes, such as inflammation, oligodendrocyte abnormalities, mitochondrial dysfunction, hypoactive N-methyl-d-aspartate receptors and the impairment of fast-spiking gamma-aminobutyric acid interneurons. Such self-sustaining mechanisms may progressively worsen producing the functional and structural consequences associated with schizophrenia. Recent clinical studies have shown antioxidant treatment to be effective in ameliorating schizophrenic symptoms. Hence, identifying viable therapeutic strategies to tackle oxidative stress and the resulting physiological disturbances provide an exciting opportunity for the treatment and ultimately prevention of schizophrenia.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974172      PMCID: PMC3021756          DOI: 10.1016/j.neubiorev.2010.10.008

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  311 in total

Review 1.  Factors contributing to the outcome of oxidative damage to nucleic acids.

Authors:  Mark D Evans; Marcus S Cooke
Journal:  Bioessays       Date:  2004-05       Impact factor: 4.345

Review 2.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 3.  Epigenetic mechanisms in the context of complex diseases.

Authors:  J van Vliet; N A Oates; E Whitelaw
Journal:  Cell Mol Life Sci       Date:  2007-06       Impact factor: 9.261

Review 4.  Redox regulation of cellular stress response in neurodegenerative disorders.

Authors:  Vittorio Calabrese; Eleonora Guagliano; Maria Sapienza; Cesare Mancuso; D Allan Butterfield; Anna Maria Giuffrida Stella
Journal:  Ital J Biochem       Date:  2006 Sep-Dec

Review 5.  Redox regulation of transcriptional activators.

Authors:  Y Sun; L W Oberley
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

6.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

Authors:  Mirjana Tosic; Jurg Ott; Sandra Barral; Pierre Bovet; Patricia Deppen; Fulvia Gheorghita; Marie-Louise Matthey; Josef Parnas; Martin Preisig; Michael Saraga; Alessandra Solida; Sally Timm; August G Wang; Thomas Werge; Michel Cuénod; Kim Quang Do
Journal:  Am J Hum Genet       Date:  2006-07-31       Impact factor: 11.025

7.  Severe tardive dyskinesia in affective disorders: treatment with vitamin E and C.

Authors:  Nikolaus Michael; Hildegard Sourgens; Volker Arolt; Andreas Erfurth
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

8.  Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.

Authors:  Kyu-hyang Cho; Hyun-ju Kim; Bernardo Rodriguez-Iturbe; Nosratola D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-06

9.  Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia.

Authors:  Erin A Hazlett; Monte S Buchsbaum; Eileen Kemether; Rachel Bloom; Jimcy Platholi; Adam M Brickman; Lina Shihabuddin; Cheuk Tang; William Byne
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

10.  Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility.

Authors:  Caroline Wass; Lennart Svensson; Kim Fejgin; Erik Pålsson; Trevor Archer; Jörgen A Engel; Daniel Klamer
Journal:  Pharmacol Biochem Behav       Date:  2008-01-26       Impact factor: 3.533

View more
  119 in total

1.  Deletion of selenoprotein P results in impaired function of parvalbumin interneurons and alterations in fear learning and sensorimotor gating.

Authors:  M W Pitts; A V Raman; A C Hashimoto; C Todorovic; R A Nichols; M J Berry
Journal:  Neuroscience       Date:  2012-02-21       Impact factor: 3.590

2.  Increased extracellular clusterin in the prefrontal cortex in schizophrenia.

Authors:  Katina M Athanas; Sarah L Mauney; Tsung-Ung W Woo
Journal:  Schizophr Res       Date:  2015-10-21       Impact factor: 4.939

3.  Interaction of clozapine and its nitrenium ion with rat D2 dopamine receptors: in vitro binding and computational study.

Authors:  Sébastien Dilly; Jean-François Liégeois
Journal:  J Comput Aided Mol Des       Date:  2010-12-24       Impact factor: 3.686

4.  Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients.

Authors:  A Monin; P S Baumann; A Griffa; L Xin; R Mekle; M Fournier; C Butticaz; M Klaey; J H Cabungcal; P Steullet; C Ferrari; M Cuenod; R Gruetter; J P Thiran; P Hagmann; P Conus; K Q Do
Journal:  Mol Psychiatry       Date:  2014-08-26       Impact factor: 15.992

5.  Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.

Authors:  Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry
Journal:  Early Interv Psychiatry       Date:  2017-07-18       Impact factor: 2.732

Review 6.  Inflammation and schizophrenia.

Authors:  Brian Kirkpatrick; Brian J Miller
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

7.  Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice.

Authors:  Olajide S Annafi; Oritoke M Aluko; Anthony T Eduviere; Osarume Omorogbe; Solomon Umukoro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-13       Impact factor: 3.000

8.  A Comprehensive Analysis of Nuclear-Encoded Mitochondrial Genes in Schizophrenia.

Authors:  Vanessa F Gonçalves; Carolina Cappi; Christian M Hagen; Adolfo Sequeira; Marquis P Vawter; Andriy Derkach; Clement C Zai; Paula L Hedley; Jonas Bybjerg-Grauholm; Jennie G Pouget; Ari B Cuperfain; Patrick F Sullivan; Michael Christiansen; James L Kennedy; Lei Sun
Journal:  Biol Psychiatry       Date:  2018-03-15       Impact factor: 13.382

9.  Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats.

Authors:  Georgia Georgiadou; Vasilios Grivas; Petros A Tarantilis; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

10.  Redox Dysregulation in Schizophrenia Revealed by in vivo NAD+/NADH Measurement.

Authors:  Sang-Young Kim; Bruce M Cohen; Xi Chen; Scott E Lukas; Ann K Shinn; A Cagri Yuksel; Tao Li; Fei Du; Dost Öngür
Journal:  Schizophr Bull       Date:  2016-09-24       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.